

Sonoma Pharmaceuticals, Inc.

Investor Presentation

April 9, 2024



Legal Disclaimers

INVESTOR PRESENTATION

This communication is for informational purposes only. The information contained herein does not purport to be all-inclusive. The data contained herein is derived from various internal and external sources. No representation is made as to the reasonableness of the assumptions made within or the accuracy or completeness of any information contained herein. Any data on past performance is no indication as to future performance. Sonoma Pharmaceuticals, Inc. and its subsidiaries (“Sonoma” or, the “Company”) assumes no obligation to update the information in this communication. This presentation is not an offer to buy or the solicitation of an offer to sell Sonoma securities.

FORWARD-LOOKING STATEMENTS

Except for historical information herein, matters set forth in this presentation are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries.

These forward-looking statements are identified by the use of words such as “believe,” “achieve,” and “expect,” among others. Forward-looking statements in this presentation are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, the Company will not have sufficient capital to implement its business plan, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

TRADEMARKS AND INTELLECTUAL PROPERTY

All trademarks, service marks, and trade names of the Company and its subsidiaries or affiliates used herein are trademarks, service marks, or registered trademarks of the Company as noted herein. Any other product, company names, or logos mentioned herein are the trademarks and/or intellectual property of their respective owners.





About Sonoma

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin.

Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners.

Investment Highlights

**Hypochlorous
Acid Industry
Leader**

Over 20 years of experience developing and manufacturing products containing HOCl, over 100 research articles, papers and clinical and case studies, over 50 active U.S. and international patents, and continual product innovation

21 U.S. FDA clearances as 510(k) medical devices, CE marks for over 39 products, and extensive worldwide regulatory clearances

Utilized on millions of patients worldwide without a single report of serious adverse effect
Products do not contain benzene or other harmful chemicals

Focused on billion-dollar markets in Rx and OTC dermatology, wound care, eye, oral and nasal care, podiatry, animal health and non-toxic disinfectants, cleansing common injuries and managing irritations

Robust and diverse international partner network selling into over 55 countries and extensive worldwide regulatory clearances means products can be commercialized faster

FDA registered medical device manufacturing capabilities in Mexico lowers COGS and creates opportunities for volume plays

**Diverse
Global
Healthcare
Business**

Wide Range of Applications



Wound Care



Dermatology



Eye Care



Oral and Dental Care



Animal Health Care



Surface Disinfectants



Podiatry



Nasal Care



Sonoma's Microcyn® Technology



Patented, Stabilized Triple-Action Topical Technology

- HOCl kills microbes including bacteria, fungi and viruses while assisting healing
- Relieves pain and itch
- Improves wound care by cleaning and moistening the wound and peri-wound area
- Safely manage skin abrasions, lacerations, minor irritations, cuts, burns, and intact skin
- Applications in dermatology include atopic dermatitis, scar treatment and daily care

May replace other treatments with side effects or health concerns

- Overused antibiotics may cause deadly epidemics such as MRSA
- May replace steroids for some patients
- Avoids harmful ingredients such as benzoyl peroxide

Cost Effective

- Reduces hospital/physician visits
- Medicare/hospital savings from reduced hospital stays



Sonoma's Microcyn® Technology



Unparalleled Safety

- No drug-to-drug interaction or contraindications
- Millions of patients treated worldwide without a single report of serious adverse effect
- 30+ human clinical trials with over 1,500 patients
- Products contain all-natural hypochlorous acid

Commercially Competitive

- Longer shelf life than most competitors while retaining efficacy
- Available in solution, hydrogels and in combination with silicone for scar treatment
- White label available with custom packaging and design
- Established Microcyn® brand
- State of the art manufacturing with pharmaceutical-grade water system



Safety in Dermatology Products

Recently, there has been concern by dermatologists that popular **dermatology products** can form **benzene**, a known carcinogen.

- *Citizen petition by Valisure, LLC, an independent testing laboratory for pharmaceuticals, requested an FDA recall of certain over-the-counter and prescription dermatology products containing benzoyl peroxide.*
- *Testing by Valisure showed that benzoyl peroxide in dermatology products from major brands including **Proactiv**, **Clearasil**, and **CeraVe**, can form benzene, a known human carcinogen, at unacceptably high levels.*
- *Previous testing by Valisure has found unacceptably high levels of benzene in common hand sanitizers, as well as in after-sun products by brands such as **Neutrogena**.*

Sonoma's products offer a safe yet highly effective alternative for consumers concerned with harmful ingredients in skin care products.

Safety in Eye Care

The FDA recently issued safety warnings for certain eye products after finding insanitary conditions in the manufacturing facilities and positive bacterial test results from environmental sampling.

- *The warnings in October 2023 applied to eye drops by brands such as **CVS**, **Rite Aid**, **Target** and **Walmart**, which were then voluntarily recalled by the manufacturer.*¹
- *Sonoma owns its own state-of-the-art manufacturing facility, used to manufacture all of its products and subject to strict FDA guidelines.*
- *Sonoma's eye care products, like all of its products, are extremely safe, and contain all-natural ingredients with no cytotoxins.*

1. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-consumers-not-purchase-or-use-certain-eye-drops-several-major-brands-due-risk-eye>

Over 100 research articles and case and clinical studies showcasing both the efficacy and safety of our Microcyn® technology

Received: 26 June 2019 | Revised: 25 November 2019 | Accepted: 10 December 2019
DOI: 10.1111/jocd.13280

REVIEW ARTICLE



Topical stabilized hypochlorous acid: The future gold standard for wound care and scar management in dermatologic and plastic surgery procedures

Michael H. Gold MD, FAAD^{1,2,3,4} | Anneke Andriessen PhD⁵ | Ashish C. Bhatia MD, FAAD^{6,7} | Patrick Bitter Jr MD, FAAD⁸ | Suneel Chilukuri MD, FAAD, FACMS^{9,10} | Joel L. Cohen MD, FAAD, FACMS^{11,12} | Chris W. Robb MD, PhD¹³

¹Gold Skin Care Center, Nashville, TN, USA
²Tennessee Clinical Research Center, Nashville, TN, USA
³Vanderbilt University School of Nursing, Nashville, TN, USA
⁴School of Medicine, Meharry Medical College, Nashville, TN, USA
⁵Andriessen Consultants & Radboud UMC, Nijmegen, The Netherlands
⁶Northwestern University - Feinberg School of Medicine, Chicago, IL, USA
⁷Qid Dermatology, Itasca, IL, USA
⁸Advanced Aesthetic Dermatology, Los Gatos, CA, USA
⁹Refresh Dermatology, Houston, TX, USA
¹⁰Baylor College of Medicine, Houston, TX, USA
¹¹USA
¹²AboutSkin Dermatology and DermSurgery, Greenwood Village and Lone Tree, CO, USA
¹³University of California Irvine Department of Dermatology, Irvine, CA, USA

¹⁴Skin and Allergy Center, Spring Hill, TN, USA

Correspondence
Anneke Andriessen, Zwenkgraz 25, 6581 RK Malden, The Netherlands.
Email: anneke.a@iscu.nl

Funding information
IntraDerm Pharmaceuticals, Grant/Award Number: The literature research for this review was sponsor

Abstract

Background: Hypochlorous acid (HOCl), a naturally occurring molecule produced by the immune system, is highly active against bacterial, viral, and fungal microorganisms. Moreover, HOCl is active against biofilm and increases oxygenation of the wound site to improve healing. Natural HOCl is unstable; through technology, it can be stabilized into an effective topical antiseptic agent.

Aim: This paper focuses on the use of topical stabilized HOCl in wound and scar management for pre-, peri-, and postprocedures—including its ability to reduce the occurrence hypertrophic scars and keloids. The role of the product in other skin conditions is beyond the scope of this article.


Methods: A panel comprising clinicians with experience in cosmetic and surgical procedures met late 2018 to discuss literature search results and their own current clinical experience regarding topical stabilized HOCl. The panel of key opinion leaders in dermatology and plastic surgery defined key insights and consensus statements on the direction of use for the product.

Results: Topical stabilized HOCl provides an optimal wound healing environment and, when combined with silicone, may be ideal for reducing scarring. Additionally, in contrast to chlorhexidine, HOCl, used as an antiseptic skin preparation, raises no concerns of ocular- or ototoxicity.

Conclusions: For wound care and scar management, topical stabilized HOCl conveys powerful microbicidal and antibiofilm properties, in addition to potency as a topical wound healing agent. It may offer physicians an alternative to other less desirable wound care measures.

KEYWORDS

hypertrophic scars, keloid scars, scar management, stabilized hypochlorous acid, wound care



Download : [Download high-res image \(577KB\)](#)

Download : [Download full-size image](#)

Figure 1. Stability of severe acute respiratory syndrome SARS-CoV. (a) Stability of SARS-CoV-2 in dried form. (b) Stability of SARS-CoV-2 in solution. (c) Stability of SARS-CoV in dried form. (d) Stability of SARS-CoV in solution. Legend: Blue line, 4°C; orange line, 20–25°C; grey line, 30°C;

COVER FOCUS

Optimizing Wound Healing for Cosmetic and Medical Dermatologic Procedures

Among the options for wound management is hypochlorous acid, a broad-action antimicrobial and anti-inflammatory agent.

BY ASHISH BHATIA, MD; JEFFREY HSU, MD; TODD SCHLESINGER, MD; AND ROBERT W.

Multiple factors influence wound healing. However, three primary conditions are essential for optimal wound healing with minimal risk of scarring. First, optimal wound healing requires the eradication of pathogenic bacteria and biofilm. Second, optimal wound healing requires an excellent blood supply and proper oxygenation. Finally, the proper immunological healing factors must be present in order for the wound to heal. With these optimal healing "primers" in place, the outcome is minimal scarring, rapid healing, and good structure and function of the healed wound site.

Physicians who perform aesthetic procedures, especially energy-based treatments or injections, are particularly focused on rapid healing, minimum pain, minimum down time, and optimal appearance. A controlled wound, as created with these tools and technologies, is associated with improved healing compared to uncontrolled or traumatic wounds. Nevertheless, proper wound care serves to further support healing for optimal cosmesis. Consider that, in some cases, aesthetic physicians are creating controlled wounds with the intention to revise existing scars, and the need to support wound healing becomes evident.

For dermatologists, wound care generally is focused on post-surgical management for biopsy and excision sites or post-procedural skincare following energy-based procedures or peels. At-home skin prep for excisions or Mohs micrographic surgery is not common. However, many patients interested in aesthetic procedures are advised to implement a skincare routine in advance of the procedure. In the aesthetic patient, retinoids and related compounds, botanical ingredients, growth factors, and antioxidants may be recommended individually or in combination, depending on the patient, the procedure, and the physician preference.

Increasingly, evidence suggests that the care immediately before a surgery or procedure and the healing phase can have important effects on the outcomes. For years, dermatologists have relied on conventional options for peri-procedural skincare: antiseptics to cleanse the skin immediately before a procedure, petrolatum ointments immediately after a procedure, and topical antibiotic ointments to reduce the risk of emerging infection. Evidence and experience suggests that these may not be ideal.

The antiseptic preparations most commonly used in the US are iodopovidone and chlorhexidine. Iodopovidone dyes the clothing and the hair, and associated irritation are noxious for some patients. Chlorhexidine can be toxic to tissues, especially mucous membranes. Therefore, procedural dermatologists have grown concerned about its use. However, chlorhexidine has practical benefits over betadine, and, at least has been an important option. Chlorhexidine prep hours—perhaps up to 72 hours—of antimicrobial activity can endure being washed with blood or fluids.

Use of topical antibiotic preparations for wound management is increasingly unpopular, due to concerns about the development of bacterial resistance. Furthermore, topical antibiotics confer no activity against yeasts that reside on the skin and may infect wounds. Additionally, some topical antibiotics are associated with risks for allergic dermatitis. The associated inflammation in the wound is detrimental to wound healing and may contribute to maturation, hyperpigmentation, or hypopigmentation. Alternative approaches to wound management and prevention have been emerging. The use of rich plasma (PRP), which is increasingly being ad-

Accepted: 13 February 2020
DOI: 10.1111/jocd.13230

REVIEW ARTICLE



Hypochlorous acid gel technology—Its impact on postprocedure treatment and scar prevention

Michael H. Gold MD, FAAD^{1,2,3,4} | Anneke Andriessen PhD⁵ | Steven H. Dayan MD⁶ | Sabrina G. Fabi MD⁷ | Z. Paul Lorenc MD, FACS^{8,9} | Meagan-Helen Henderson Berg MDCM¹⁰

¹Gold Skin Care Center, Nashville, TN, USA
²Tennessee Clinical Research Center, Nashville, TN, USA
³Vanderbilt University School of Nursing, Nashville, TN, USA
⁴School of Medicine, Meharry Medical College, Nashville, TN, USA
⁵Andriessen Consultants & Radboud UMC, Nijmegen, The Netherlands
⁶Department of Otolaryngology, Division of Facial Plastic and Reconstructive Surgery, University of Illinois, Chicago, IL, USA
⁷Cosmetic Laser Dermatology, San Diego, CA, USA
⁸Lorenc Aesthetic Plastic Surgery Center, New York, NY, USA
⁹Department of Plastic Surgery, Lenox Hill Hospital, New York, NY, USA
¹⁰Faculty of Medicine, MCGill University, Montreal, Canada

Correspondence
Dr Anneke Andriessen, Zwenkgraz 25, 6581 RK Malden, The Netherlands.
Email: anneke.a@iscu.nl

Funding information
IntraDerm Pharmaceuticals, Grant/Award Number: supported literature research with an educational grant

Summary

Background: A pre- and postprocedure regime aimed at prevention of infection, reduction of inflammation and risk of scarring, is to enable optimal outcomes.

Objectives: The role of a hypochlorous acid containing spray and translucent scar gel formulation that combines modified silicon oil with hypochlorous acid, was explored for pre- and postprocedure treatment and scar management.

Methods: For this purpose a literature review was conducted to explore the value of the technology used in pre- and postprocedural regimes. A panel of dermatologists and plastic surgeons who practice in the United States discussed the summarized search results, taking into account their current clinical practice. A nominal group process for consensus was used, followed by online reviews of the manuscript.

Results: Based on panel discussions, consensus was reached regarding clinical recommendations given for postprocedure treatment and scar management. The hypochlorous acid products are produced with electrolysis and are classified among biocidal substances. The technology has demonstrated efficacy and safety for pre- and postprocedure use. The safety of hypochlorous solution use demonstrated to be comparable to that of standard local antiseptics. Small studies demonstrated better results with the scar gel compared to silicone gel regarding the appearance of hypertrophic and keloid scars, relief of associated pruritus and pain.

Conclusions: A postprocedure regime using this technology, aimed at preventing infection, reducing inflammation, and promoting healing is proposed to have benefits over current regimes as it appears to be effective, safe, and well tolerated.

KEYWORDS

hypochlorous acid technology, postprocedure care, scar management

1 | INTRODUCTION

Clinician concerns over pre- and postprocedure care and scar management are at the forefront. They are balancing antiseptic properties and cytotoxicity with severity of colonization to assure a proper healing environment and enhance outcomes. Our immune system

naturally produces a compound called hypochlorous acid (HOCl) to eradicate bacteria and other invading pathogens within the body. This compound has also shown antipruritic and anti-inflammatory effects.^{1,2} A HOCl containing spray or super-oxidized solution for cleansing, irrigation, and disinfection of surgical sites (Alevyn-Dermal Spray) may decrease the risk of infection and optimize surgical

CUTTING EDGE MANUFACTURING



Currently operating at 30% capacity, with margin of approximately 35%



- 57,153 square foot state-of-the-art facility
- ISO 9001, ISO 13485 and cGMP certified
- MOH, KFDA, SFDA, KSA, TGA, EN, Biocide and numerous other national listings and approvals
- Shipping to over 55 countries
- Highly trained staff of 162 employees

Flexible operations capable of CUSTOM LABELING, SIZING, PACKAGING & DISPENSE MODES

High or small volume, large or small batch, delivered in 8-12 weeks


Manufacturing Facility



Located in Guadalajara, Mexico



Laboratory




Materials Testing Laboratory



Water Treatment System



Product



Air Systems



Packaging Area



Labeling



Boxing



Ready for shipment



Warehouse

Robust International Distribution Network

OVER 40 GLOBAL PARTNERS generating strong revenues internationally and in the U.S.

- Expand presence in new markets by replicating what works in existing markets
- Continue to add new distribution partners and grow existing relationships
- Continue co-development of innovative new products with partners in the U.S. and internationally
- Work with partners to seek new approvals and certifications



Growth Strategy

Continue to introduce new high margin products

- Launch new applications of Sonoma's Microcyn® technology for consumer-focused products, including in the dermatology and aesthetic space

Manufacturing capabilities can support significant future growth, leading to improved margins overall

- Efficient, flexible and FDA-regulated manufacturing facility currently operating at only 30% capacity

Expand Rx and OTC reach in U.S.

- Increase sales of dermatology products through the direct dispense model that generates Sonoma's highest margins
- Increase direct-to-consumer marketing in niche markets

Invest in R&D to expand commercialization opportunities

- Introduce new technology to new markets
- Fully commercialize robust pipeline of new products via direct-to-consumer sales or distribution partnerships

New Market Opportunities

Sonoma is expanding its partnerships and product offerings in the all-natural skin care and medical spa industries.

- The global **natural skin care** products market size was valued at \$6.7 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.6% from 2022 to 2030.¹
- The global **medical spa** market size was valued at \$16.4 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 14.97% from 2023 to 2030.²
 - North America dominated the medical spa market with a share of 41.5% in 2022, attributable in part to increasing demand for minimally invasive aesthetic procedures.³

Sonoma also continues to expand its presence in the global **animal health** market that was valued at \$39.9 billion in 2021 and is expected to witness a compound annual growth rate (CAGR) of 10.0% from 2022 to 2030.⁴

1. Grand View Research, *Natural Skin Care Products Market Report, 2022-2030*, available at <https://www.grandviewresearch.com/industry-analysis/natural-skin-care-products-market>

2. Grand View Research, *Medical Spa Market Size, Share & Growth Analysis Report 2030*, available at <https://www.grandviewresearch.com/industry-analysis/medical-spa-market>

3. *Ibid.*

4. Grand View Research, *Animal Health Market Size & Share Report, 2022-2030*, available at <https://www.grandviewresearch.com/industry-analysis/animal-health-market>



Recent Business Developments

Introduction of new products using our Microcyn® technology

- On April 9, 2024, Sonoma announced expansion of its **Microcyn® Negative Pressure Wound Therapy Solution** products line, now available in 250mL, 450mL and 990mL sizes to meet the diverse needs of healthcare professionals and patients.
- On January 23, 2024, Sonoma launched **Lumacyn™ Clarifying Mist**, a new direct-to-consumer skincare product, in the United States. Lumacyn is an all-natural daily toner formulated with Microcyn® technology to soothe the skin and relieve irritation.
- On January 5, 2024, Sonoma entered into an agreement with **NovaBay Pharmaceuticals, Inc.** for the sale and marketing of **Avenova®-branded products** in the European Union, based on Sonoma's existing eye product **Ocudox®** and sold through Sonoma's established European distribution network.
- On June 8, 2023, Sonoma announced a new application of its Microcyn® technology for **intraoperative pulse lavage irrigation treatment**, which can replace commonly used IV bags in a variety of surgical procedures. It is in trial use by hospitals in Europe and launched in the U.S. in November 2023.
- On April 11, 2023, Sonoma launched **Podiacyn™ Advanced Everyday Foot Care** direct to consumers for over-the-counter use in the United States.



Recent Business Developments

Expanding commercialization opportunities by investing in R&D

- In March 2023, Sonoma announced new EPA claims for its **Nanocyn® Hospital-Grade Disinfectant** for effective use against **MRSA**, **Salmonella**, **Norovirus**, **Poliovirus**, and as a **fungicide**. Nanocyn was previously approved for use against **COVID-19** as well as emerging pathogens including **Ebola virus**, **Mpox**, and **SARS-CoV-2**. Nanocyn also received the esteemed **Green Seal® Certification** after surpassing a series of rigorous standards that measure environmental health, sustainability and product performance.
- **Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel** was awarded the **NATIONAL ECZEMA ASSOCIATION SEAL OF ACCEPTANCE™**
- A recent publication in the journal *Neurourology and Urodynamics* highlighted the potential for **Microdox®** in the management of urinary tract infections, or UTIs, in children with neurogenic or non-neurogenic bladder dysfunction, concluding that multi-center trials are needed.¹



1. Singh G-K, Deshpande A, Schlegel G, Starkey M, Taghavi K. The rationale for bladder washouts in children with neurogenic bladder. *Neurourol Urodyn*. 2024;1-6. doi:10.1002/nau.25450

Recent Business Developments

Continuously expanding our distributor network

- Entered into a distribution agreement with **Daewoong Pharmaceutical Co., Ltd.**, one of the largest pharmaceutical companies in South Korea, in January 2023 for the marketing and distribution of Primocyn™ Skin Solution products
- Sonoma's Microcyn® Rx products, including wound care, prescription dermatology products Celacyn® and Levicyn®, and prescription eye care Acuicyn®, received a Distribution and Pricing Agreement (DAPA) in January 2023 for distribution by the Defense Logistics Agency (DLA), enabling our partner, **EMC Pharma, LLC** to enter into distribution agreements for these products with federal customers
- In April 2023, our partner **Te Arai BioFarma Limited** launched BabySoothe for diaper rash applications in Taiwan
- In April 2024, **Te Arai** launched Microdacyn for wound care in Taiwan
- Our partner **Microderm Technologies** recently launched Dermodacyn for wound care applications in Thailand
- Our partner **Brill Pharma SL** is now selling Sonoma's eye care products in Italy, Spain and Portugal and recently launched in Germany
- Our MicrocynAH® products are now available through Pets at Home, with over 450 stores across the UK, through our partner **Manna Pro Products, LLC**

Management

Amy Trombly **CEO**

Amy Trombly is our Chief Executive Officer and also serves on our Board of Directors. She counseled public companies for over two decades in corporate and securities law and mergers and acquisitions, including as the owner and manager of Trombly Business Law, PC. In her earlier career, Ms. Trombly was a Vice President at State Street Bank and Special Counsel at the U.S. Securities and Exchange Commission. Ms. Trombly is a member of the bar in Massachusetts and Colorado.

Bruce Thornton **COO**

Bruce Thornton has served as our Chief Operating Officer, Vice President of Global Operations, and US General Manager since 2004, and currently as Executive Vice President and Chief Operating Officer. He served as Vice President of Operations for Jomed (formerly EndoSonic Corp.) from January 1999 to September 2003, and as Vice President of Manufacturing for Volcano Therapeutics, an international medical device company, following its acquisition of Jomed, until March 2004. Mr. Thornton received a B.S. in Aeronautical Science from Embry-Riddle Aeronautical University and an M.B.A. from National University. He also has served in the US Army.

Jerry Dvonch **CFO**

Mr. Dvonch serves as our Chief Financial Officer. He joined us from the SpineCenter Atlanta where he was the controller and Senior Vice President of Finance and Accounting since March 2017. From March 2016 to April 2016 he was a consultant controller for DS Healthcare Group, Inc. Prior to that he was the director for external reporting and director of finance of NeoGenomics Laboratories from July 2005 to July 2015. He has over 10 years of experience with SEC reporting. Mr. Dvonch is a licensed Certified Public Accountant in New York. He holds a Master of Business Administration in Finance from the University of Rochester and a Bachelor of Business Administration in Accounting from Niagara University.

Key Financial Metrics

	Nine Months Ended December 31, 2023* (unaudited)	Nine Months Ended December 31, 2022* (unaudited)	Year Ended March 31, 2023*	Year Ended March 31, 2022*
Total Revenues	\$9,296	\$10,258	\$13,272	\$12,628
Gross Profit	\$3,654	\$3,613	\$4,477	\$3,993
Operating Expenses	\$6,946	\$7,036	\$9,047	\$9,880
Net Income (Loss)	\$(3,768)	\$(3,843)	\$(5,151)	\$(5,086)
EBITDA loss	\$(1,985)	\$(1,597)	\$(3,776)	\$(5,318)
Cash & Cash equivalents	\$2,406	\$2,634	\$3,820	\$7,396
Working capital	\$9,428	\$7,298	\$10,081	\$10,611
Shareholders' Equity	\$6,692	\$5,559	\$7,977	\$8,697

* dollars in thousands



Revenue Metrics

Revenues by revenue source:

	Nine Months Ended December 31,		Year Ended March 31,	
	2023	2022	2023	2022
Human Care	\$ 7,286	\$ 7,050	\$ 9,426	\$ 9,010
Animal Care	1,688	1,957	2,500	3,169
Service and Royalty	322	1,251	1,346	449
	\$ 9,296	\$ 10,258	\$ 13,272	\$ 12,628

Revenues by geographic region:

	Nine Months Ended December 31,		Year Ended March 31,	
	2023	2022	2023	2022
United States	\$ 2,214	\$ 2,603	\$ 3,428	\$ 3,807
Europe	3,488	3,117	4,051	3,410
Asia	1,730	1,952	2,451	2,350
Latin America	1,165	1,827	2,383	2,095
Rest of the World	699	759	959	966
Total	\$ 9,296	\$ 10,258	\$ 13,272	\$ 12,628

* in thousands



APPENDIX: Product Portfolio



Diverse Product Portfolio

United States

Reliefacyn

Itch, Burn, Rash & Pain Care



Regenacyn

Scar Gel



Podiacyn

Everyday Foot Care



Microcyn Rx

Skin & Wound Care



Acucyn

Antimicrobial Eyelid & Eyelash Hygiene



Nanocyn

Hospital Grade Disinfectant



Ocucyn

Eyelid & Eyelash Cleanser



Pediacyc

Skin Care & First Aid for Children



Microcyn OTC

Wound & Skin Cleanser



Rejuvacyc

Skin Repair



Epicyn

Antimicrobial Facial Cleanser



Levicyn

Antimicrobial Dermal Spray



Celacyc

Scar Management Gel



Lumacyn™ Clarifying Mist introduced January 2024

- New high-end direct to consumer skincare product for daily management of skin irritations



U.S. office dispense products exclusively for skin care professionals



- Generates highest margins for Sonoma
- Focused marketing to med spas and dermatology offices, which can resell products to their clients for a substantial margin

U.S. Animal Health Care

MicrocynAH[®] family of advanced animal healthcare products, safe to use on pets and livestock, and perfect for hot spots, pink eye, scratches, skin rashes and ulcers, cuts, burns, post-surgical sites, irritated skin and lacerations.

- Sold in national pet-store retail chains and specialty stores such as **PetSmart**, **Tractor Supply**, **Cabela's** and **Bass Pro Shops**.



MicrocynVS[®] veterinarian-strength animal care for use in vet clinics and animal hospitals.



EU Products

Solutions that work naturally **for everybody**

Mucoclyns®
Decontamination solution



Exposure to germs and pathogens

Microdacyn60®
Oral Care



Mouth and throat infections

Sinudox®
Nasal care



Blocked nose or sinuses

Ocudox®
Eye lid solution



Blepharitis treatment

Epicyn®
Dermatology



Keloid or hypertrophic scar

Gramaderm®
Dermatology



Acne treatment

Pediacyn®
Dermatology



Atopic Dermatitis

Microdacyn60®
Wound Care



MicrocynAH®
Animal Health Care



Direct-to-consumer products available through Shopify, Amazon and Amazon EU



U.S. Products



EU Products



Middle East

Microdacyn Wound Care



Microsafe

Face Cool, Anti-Microbial, Baby Cool, Foot Cool, Lady Cool



Microsafe Disinfectant & Sanitizer



Latin America

Celacyn

Scar Management Gel



Gramacyn

Kit for Acne Skin



Australia and New Zealand

Microdacyn

Surgical Irrigation and Wound Treatment



Epicyn

Treat Scars Right from the Start



Microdox

Super-Oxidised Solution Bladder & Catheter Rinse



Asia

Singapore, Malaysia, Thailand,
Indonesia
Wound Care



South Korea

BioDerm
Wound Care



Biodacyn60



China
Microcyn



The Philippines

Microdacyn



Hong Kong
Microdacyn60 Oral Care



MicrocynAH



THANK YOU

Sonoma Pharmaceuticals Inc.

5445 Conestoga Court, Suite 150 Boulder, CO 80301

United States of America

Phone: 1-(800) 759.9305

Email: busdev@sonomapharma.com

Website: www.sonomapharma.com



NASDAQ: SNOA